Novartis (NOVN) Given a CHF 89 Price Target by Baader Bank Analysts

Baader Bank set a CHF 89 price objective on Novartis (VTX:NOVN) in a report published on Friday. The firm currently has a buy rating on the stock.

Other analysts have also issued research reports about the stock. Barclays set a CHF 70 price objective on shares of Novartis and gave the stock a sell rating in a research report on Monday, June 25th. JPMorgan Chase & Co. set a CHF 84 price objective on shares of Novartis and gave the stock a neutral rating in a research report on Tuesday, July 17th. Deutsche Bank set a CHF 89 price objective on shares of Novartis and gave the stock a neutral rating in a research report on Tuesday, July 3rd. Cfra set a CHF 88 price objective on shares of Novartis and gave the stock a buy rating in a research report on Friday, June 29th. Finally, Berenberg Bank set a CHF 90 price objective on shares of Novartis and gave the stock a neutral rating in a research report on Friday, June 29th. Eleven research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Novartis has an average rating of Hold and an average target price of CHF 88.57.

Novartis stock traded up CHF 0.34 during midday trading on Friday, hitting CHF 78.38. 11,210,000 shares of the stock were exchanged, compared to its average volume of 5,980,000. Novartis has a 52-week low of CHF 72.45 and a 52-week high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Recommended Story: What is the Dividend Aristocrat Index?

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply